Coherus Oncology (CHRS) Gross Margin (2019 - 2026)

Coherus Oncology has disclosed Gross Margin across 8 years of filings, most recently posting 69.02% for Q1 2026.

• Gross Margin for Q1 2026 came in at 69.02%, up 393.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 68.06% (down 56.0% YoY), and the FY2025 annual result was 67.24%, up 31.0% from the prior year.
• Gross Margin came in at 69.02% for Q1 2026 at Coherus Oncology, up from 68.27% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 84.41% in Q1 2022 to a low of 7.6% in Q4 2023.
• The 5-year median for Gross Margin is 65.09% (2025), against an average of 58.98%.
• Across the five-year window, Gross Margin sank 6108 bps in 2023 and jumped 5684 bps in 2024, its largest moves.
• Coherus Oncology's Gross Margin stood at 68.68% in 2022, then plunged by 89 bps to 7.6% in 2023, then surged by 748 bps to 64.44% in 2024, then grew by 6 bps to 68.27% in 2025, then grew by 1 bps to 69.02% in 2026.
• The last three Gross Margin figures came in at 69.02% (Q1 2026), 68.27% (Q4 2025), and 67.84% (Q3 2025), per Business Quant data.